Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Michigan Rogel Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05956041CT.gov Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | — | Recruiting | — | — | — |
NCT04960618CT.gov Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | — | Active Not Recruiting | — | — | — |
NCT03695471CT.gov Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | — | Completed | — | — | — |
NCT03385226CT.gov A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) | — | Active Not Recruiting | — | — | — |
NCT03063632CT.gov Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | — | Completed | — | — | — |
NCT02243579CT.gov Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mycosis Fungoides And Variants
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | University of Michigan Rogel Cancer Center | P2 | BB · 64 |
| Fludarabine | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BB |
| Romidepsin | Northwestern University | P2 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Mogamulizumab | University of Michigan Rogel Cancer Center | P2 | B |
| Lenalidomide | Northwestern University | P2 | B |
| Lacutamab | Innate Pharma | P2 | B |
| Interferon Gamma-1B | National Cancer Institute (NCI) | P2 | B |
| VITPSO | European Organisation for Research and Treatment of Cancer - EORTC | P2 | CCC |
+20 more in the Mycosis Fungoides And Variants cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Mycosis Fungoides And Variants. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-mycosis-fungoides-and-variants
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →